At a glance
ClinicalIndex Comparison RecordN/ACompleted· 76 enrolled
Drug / intervention
normal subject +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diagnosis of Gastroduodenal Diseases by Proteiomic Fingerprints of Gastric Juice
In Brief
A clinical study evaluating normal subject and gastric cancer for Gastric Cancer. Completed, enrolled 76 participants across 2 sites.
Detailed Summary
No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potential biomarkers of gastric cancer in gastric juice. The aim of this study was to develop a novel non-invasive modality for detecting gastric cancer by measurement of biomarkers in gastric juice.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesTaiwan
CollaboratorsNational Science and Technology Council, Taiwan
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedFeb 2009
Primary CompletionMar 2011
TodayJul 2026
First PostedFeb 3, 2009
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.4 years ago
Interventions
normal subjectother
biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
gastric cancerother
biomarker in gastric juice, e.g., alpha 1-antitrypsin